04:32 AM EST, 11/12/2025 (MT Newswires) -- DBV Technologies ( DBVT ) said late Tuesday it has completed the last patient visit in a phase 3 clinical trial of a patch in peanut allergic children aged four to seven years.

The company said it is on track to report topline data from the study in Q4.

The trial is a 12-month study evaluating the efficacy and safety of the Viaskin Peanut patch in 654 individuals across 86 sites in the US, Canada, Europe, the UK and Australia.

Shares of the company traded more than 8% in Wednesday's premarket activity.

Price: 14.50, Change: +1.16, Percent Change: +8.70